Event Details
Welcome to the official page for Deepcell's presentation at the 42nd annual J.P. Morgan Healthcare Conference. Explore the groundbreaking achievements and insights shared by CEO Maddison Masaeli during the event.
Presentation
%20(1).png?width=1200&height=400&name=May%2024%20gif%20(1200%20x%20400%20px)%20(1).png)
Unveiling the unseen, reimagining biology
At JPM2024 Deepcell revealed that it has trained a first of its kind generative morphology model that will allow researchers to explore, in silico, morphological responses of a single cell to biological or environmental changes. Key advantages of incorporating GenAI include:
- Interpreting Deepcell’s Human Foundation Model (HFM)
- Integrating morphology with other omics for multimodal capabilities
- Generating and refine hypotheses
Key Developments & Announcements
- The first REM-I instrument was recently installed for testing at an academic institution where the platform will be used in Alzheimer’s disease research.
- In addition to direct sales in the United States and Western Europe, Deepcell has established relationships with a global network of distributors facilitating the company’s reach into Asia and Middle East, and will expand to all markets in the coming year.
- The company is in the process of manufacturing REM-I instruments to fulfill orders from diverse customers across three continents.
